Literature DB >> 28282800

FBLN-4 and BCRP genes as two prognostic markers are downregulated in breast cancer tissue.

Jamshid Motalebzadeh1, Frouzandeh Mahjoubi1, Nahid Nafissi2, Maria Hashemian3, Mohsen Taheri1, Younes Hosseinpour1.   

Abstract

BACKGROUND: Fibulin-4 (FBLN-4) is an extracellular glycoprotein that is upregulated in some cancer and is khown as prognostic marker in ovarian and cervical cancer. Breast cancer resistance protein (BCRP) is an ATP-binding cassette transporter that facilitates the efflux of various anticancer drugs from the cell and cause MDR phenotype in breast tumors. Many studies are available that indicat overexpression of BCRP gene in breast cancer.
OBJECTIVE: In the present study we aimed to analyze the expression level of FBLN-4 and BCRP in Iranian breast cancer patients.
METHODS: We collected 40 samples of breast cancer and normal tissue from Tehran Khatam-al-Anbia hospital. To analyze the gene expression by using Real Time RT-PCR FBLN-4 and BCRP gene expression level were measured and then the association of gene expression with breast cancer were determined.
RESULTS: Surprisingly the expression level of FBLN-4 and BCRP genes were downregulated in tumor tissues compared to adjacent normal tissues. Comparison of the gene expression and clinico-pathology reports indicate FBLN-4 gene expression was associated with breast cancer histological grade. We found no correlation between the expressions of BCRP gene with any clinico-pathological characters.
CONCLUSION: Interestingly and in contrast with our expectation, we found that the expression level of FBLN-4 and BCRP were downregulated in tumor compared to adjacent normal tissues. FBLN-4 was associated with grade histology and therefore can be considered as a potential prognostic biomarker.

Entities:  

Keywords:  BCRP; Fibulin-4; breast cancer; prognostic marker

Mesh:

Substances:

Year:  2017        PMID: 28282800     DOI: 10.3233/CBM-160335

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  4 in total

1.  Prognostic Value of FBXO39 and ETS-1 but not BMI-1 in Iranian Colorectal Cancer Patients

Authors:  Jamshid Motalebzadeh; Samira Shabani; Saeedeh Rezayati; Narges Shakournia; Rezvan Mirzaei; Bahar Mahjoubi; Kamal Hoseini; Frouzandeh Mahjoubi
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26

2.  EFEMP2 suppresses epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in human bladder cancer.

Authors:  Qiang Zhou; Song Chen; Mengxin Lu; Yongwen Luo; Gang Wang; Yu Xiao; Lingao Ju; Xinghuan Wang
Journal:  Int J Biol Sci       Date:  2019-08-08       Impact factor: 10.750

3.  EFEMP2 Inhibits Breast Cancer Invasion And Metastasis In Vitro And In Vivo.

Authors:  Ning Kang; Jijun Zhou; Jia Xu; Dongsheng Zhou; Weichen Shi
Journal:  Onco Targets Ther       Date:  2019-10-30       Impact factor: 4.147

4.  EFEMP2 Suppresses the Invasion of Lung Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition (EMT) and Down-Regulating MMPs.

Authors:  Liang Song; Xiang-Xin Li; Xiang-Yan Liu; Zhou Wang; Yang Yu; Mo Shi; Bin Jiang; Xiao-Peng He
Journal:  Onco Targets Ther       Date:  2020-02-14       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.